PURE PROFESSIONAL - GLYCO PURE
Food supplement declared in France, declaration No 2024-6-164, decision dated 4 June 2024
PURE PROFESSIONAL - GLYCO PURE is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- TSUNAMI NUTRITION SRL
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Powder
- Daily dose
- 33,3 g par jour
- Intended populations
- Men, Women
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women
- Flavourings
- MELON D'EAU
Declaration 142385, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Prunus cerasus L. | Fruit | Poudre (de plantes séchées ou broyées) | 250 mg |
Other active ingredients
| Name | Per day |
|---|---|
| dextrine | not declared |
| L-Glutamine | not declared |
| L-leucine | not declared |
| Arginine | not declared |
| Lysine | not declared |
| L-isoleucine | not declared |
| L-valine | not declared |
| Glycine | not declared |
| Chlorhydrate de L-ornithine | not declared |
| Thréonine | not declared |
| Bêta-alanine | not declared |
| Hydroxyméthylbutyrate | not declared |
| Cystéine | not declared |
| Histidine | not declared |
| Citrulline | not declared |
| Phénylalanine | not declared |
| Méthionine | not declared |
| Tyrosine | not declared |
| Tryptophane | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Picolinate de chrome | Chrome | pas de limite (données insuffisantes) | 25 µg |
| Citrate de potassium | Potassium | pas de limite (données insuffisantes) | 80 mg |
Additives
E330, E551, E955, E950
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ne pas dépasser la dose journalière recommandée. Ne pas laisser à la portée des jeunes enfants. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée. Un mode de vie sain et une alimentation variée et équilibrée sont importants. Réservé à l'adulte. Déconseillés chez les femmes enceintes ou allaitantes. Déconseillé aux personnes âgées ou atteintes de néphropathie.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- L-Glutamine
Read the warning, when it applies and the studies cited
L-Glutamine
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Arginine
Read the warning, when it applies and the studies cited
L-ARGININE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.
Condition of application: Improvement in exercise capacity in individuals with stable CVD.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.
Applies to products providing more than 0.42 g of L-Arginine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).
Sources cited by Health Canada (7)
- Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. International Journal of Cardiology 2000;75(2-3):205-210. PubMed Randomised trial
- Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American Journal of Cardiology 1997;80(3):331-333. PubMed Randomised trial
- Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. L-Arginine supplementation improves exercise capacity after a heart transplant. American Journal of Clinical Nutrition. 2010. Doi: 10.3945/ajcn.2009.27881. DOI
- Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. International Journal of Sports Medicine 2006;27(7):567-572. PubMed
- Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001;163(4):887-891. PubMed Randomised trial
- Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral –arginine in patients with heart failure. Circulation 1996;93(12):2135-2141. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).
Sources cited by Health Canada (4)
- Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Journal of the American College of Cardiology 1995;26(4):1054-1061. PubMed Randomised trial
- Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. American College of Nutrition 2002;21(5):422-427. PubMed Clinical trial
- Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology 2002;39(7):1199-1203. PubMed Randomised trial
- Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. American Journal of Hypertension 2000;13(5):547-551. PubMed Randomised trial
Contraindications
Applies to products providing more than 9 g of L-Arginine, per day.
Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).
Sources cited by Health Canada (3)
- Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
- Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin Cardiol. 2009;32(11):649-652. PubMed Meta-analysis
Known adverse reactions
Applies to products providing more than 9 g of L-Arginine, per day.
When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).
Sources cited by Health Canada (4)
- Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. Journal of Clinical Investigation 1996;97(8):1989-1994. PubMed Randomised trial
- Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry 2004;15(9):534-539. PubMed
- Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of Nutrition 2007;137(6 Suppl 2):1693S-1701S. PubMed Review article
- IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington (DC): National Academies Press; 2005.
- Lysine
Read the warning, when it applies and the studies cited
LYSINE
Route of administration: Oral
Cautions and warnings
Applies to products providing more than 300 mg of lysine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Goldman and Ausiello 2004).
Sources cited by Health Canada (1)
- Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
- Tyrosine
Read the warning, when it applies and the studies cited
L-TYROSINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- PURE PROFESSIONAL - GLYCO PURE TSUNAMI NUTRITION SRL, declared in 2024 : same declared composition
- PURE PROFESSIONAL - GLYCO PURE TSUNAMI NUTRITION SRL, declared in 2024 : same declared composition
- PURE PROFESSIONAL - GLYCO PURE TSUNAMI NUTRITION SRL, declared in 2024 : same declared composition
- PURE PROFESSIONAL - GLYCO PURE TSUNAMI NUTRITION SRL, declared in 2024 : same declared composition
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.